By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PrognosDx Health today announced a deal with Accium BioScience to develop and commercialize tests based on histone biomarkers.

Palo Alto, Calif.-based PrognosDx will lend its expertise and epigenetic platform technology to the partnership, while Accium, headquartered in Seattle, will contribute its accelerator mass spectrometry platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.